Literature DB >> 11483915

Hormonal and barrier contraception and risk of upper genital tract disease in the PID Evaluation and Clinical Health (PEACH) study.

R B Ness1, D E Soper, R L Holley, J Peipert, H Randall, R L Sweet, S J Sondheimer, S L Hendrix, A Amortegui, G Trucco, D C Bass, S F Kelsey.   

Abstract

OBJECTIVE: Among women diagnosed with pelvic inflammatory disease, we examined the associations between hormonal or barrier methods of contraception and upper genital tract infection or inflammation.
METHODS: Participants were 563 patients from a treatment trial for pelvic inflammatory disease. All had pelvic pain; pelvic organ tenderness; and leukorrhea, mucopurulent cervicitis, or untreated cervicitis. Contraceptive use within the prior 4 weeks was compared among women with baseline upper genital tract gonorrhea or chlamydia, women with endometritis without upper genital tract gonorrhea or chlamydia, and women with neither upper genital tract gonorrhea or chlamydia nor endometritis.
RESULTS: Inconsistent condom use was significantly and independently associated with a 2 to 3 times elevated risk for upper genital tract infection. Upper genital tract gonorrhea or chlamydia was not significantly associated with use of oral contraceptives, use of medroxyprogesterone, condoms used consistently, nor other barrier methods.
CONCLUSION: No hormonal or barrier contraceptive method was related to a reduction in upper genital tract disease among women with clinical pelvic inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11483915     DOI: 10.1067/mob.2001.115114

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  7 in total

Review 1.  An update on pelvic inflammatory disease.

Authors:  J D C Ross
Journal:  Sex Transm Infect       Date:  2002-02       Impact factor: 3.519

Review 2.  Noncontraceptive health benefits of oral contraceptives.

Authors:  Andrew M Kaunitz
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

3.  Condom use and the risk of recurrent pelvic inflammatory disease, chronic pelvic pain, or infertility following an episode of pelvic inflammatory disease.

Authors:  Roberta B Ness; Hugh Randall; Holly E Richter; Jeffrey F Peipert; Andrea Montagno; David E Soper; Richard L Sweet; Deborah B Nelson; Diane Schubeck; Susan L Hendrix; Debra C Bass; Kevin E Kip
Journal:  Am J Public Health       Date:  2004-08       Impact factor: 9.308

4.  Risk factors associated with pelvic inflammatory disease.

Authors:  I Simms; J M Stephenson; H Mallinson; R W Peeling; K Thomas; R Gokhale; P A Rogers; P Hay; P Oakeshott; J Hopwood; H Birley; M Hernon
Journal:  Sex Transm Infect       Date:  2006-08-10       Impact factor: 3.519

5.  Analysis of Factors Driving Incident and Ascending Infection and the Role of Serum Antibody in Chlamydia trachomatis Genital Tract Infection.

Authors:  Ali N Russell; Xiaojing Zheng; Catherine M O'Connell; Brandie D Taylor; Harold C Wiesenfeld; Sharon L Hillier; Wujuan Zhong; Toni Darville
Journal:  J Infect Dis       Date:  2015-09-07       Impact factor: 5.226

Review 6.  Pelvic inflammatory disease: current concepts in pathogenesis, diagnosis and treatment.

Authors:  Caroline Mitchell; Malavika Prabhu
Journal:  Infect Dis Clin North Am       Date:  2013-10-31       Impact factor: 5.982

7.  How prevalent are symptoms and risk factors of pelvic inflammatory disease in a sexually conservative population.

Authors:  Oqba Al-Kuran; Lama Al-Mehaisen; Hamza Alduraidi; Naser Al-Husban; Balqees Attarakih; Anas Sultan; Zeina Othman; Sanal AlShárat; Shoug AlHilali; Nadia Alkouz; Noura Alibrahim; Wafaa AlMusallam
Journal:  Reprod Health       Date:  2021-05-28       Impact factor: 3.223

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.